Retatrutide 15

GL1-R3 · 15 mg · titration schedule

SCIENCE • STRENGTH • LONGEVITY

Before you draw anything. Every figure in this document assumes a 15 mg vial reconstituted with 1.5 mL of bacteriostatic water. Change either number and every unit measurement here changes with it. Confirm the milligram strength printed on your vial first.

RECONSTITUTION

Parameter	Value
Vial	15 mg
Bacteriostatic water	1.5 mL (150 units)
Concentration	10 mg/mL
Conversion	10 units = 1 mg · 1 unit = 0.1 mg
Route	Subcutaneous
Interval	Every 6 days
Reconstituted storage	2–8 °C, 28–60 days
Lyophilized storage	−20 °C, 12+ months

Let the vial and the bacteriostatic water reach room temperature.
Swab both stoppers with alcohol and let them dry.
Draw the planned volume of bacteriostatic water into a sterile syringe.
Aim the stream at the inside wall of the glass, never directly at the powder.
Roll gently for 30 to 60 seconds until fully dissolved. Never shake — shaking damages the peptide.
Confirm the solution is clear before use.
Label with product, concentration, and date, then refrigerate.

TITRATION SCHEDULE

Day	Units	Amount	Cumulative used	Remaining in vial
Day 1	10	1.0 mg	1.0 mg	14.0 mg
Day 7	10	1.0 mg	2.0 mg	13.0 mg
Day 13	15	1.5 mg	3.5 mg	11.5 mg
Day 19	15	1.5 mg	5.0 mg	10.0 mg
Day 25	15	1.5 mg	6.5 mg	8.5 mg
Day 31	20	2.0 mg	8.5 mg	6.5 mg
Day 37	20	2.0 mg	10.5 mg	4.5 mg
Day 43	25	2.5 mg	13.0 mg	2.0 mg
Day 49	25	2.5 mg	15.5 mg	Exceeds vial — see below

Vial coverage. The full nine-dose schedule draws 155 units against 150 units of solution. One 15 mg vial covers through Day 43 with 2 mg remaining — the Day 49 dose runs roughly half short. Have a second vial on hand before Day 43.

Working the titration

Advance only when the current step is tolerated. This schedule steps up every two to three doses, which is a faster ramp than the four-week holds used in clinical titration. Ramp rate drives side effects more than the absolute amount does.
Nausea is the limiting factor. If it appears, hold the current step for another two doses rather than advancing. Dropping back a step is a normal adjustment.
Other commonly reported effects include diarrhea, constipation, vomiting, and tingling or unusual skin sensation.
A 6-day interval walks the dosing day through the week. A fixed weekly day is easier to track and matches the pharmacokinetics this compound was studied on.
Taper down rather than stopping abruptly at the end of a run.
Rotate injection sites across abdomen, thigh, and flank.

CAUTIONS

This compound carries the most substantial adverse-event profile of anything in the catalog. Anyone with an existing condition or prescription should be reviewing it with a clinician rather than a protocol sheet.

Personal or family history of medullary thyroid cancer.
History of pancreatitis.
Type 1 diabetes, or any existing glucose-lowering medication — retatrutide affects insulin response through the GIP receptor.
Severe gastrointestinal disease.
Pregnancy or breastfeeding — no safety data exists.
Prohibited by WADA and will test positive.

If combining with MOTS-c

Run retatrutide alone for the first four weeks before adding anything else. Staggering the start is the only way to identify which compound caused a new symptom. Note that MOTS-c acts on glucose uptake through a separate pathway, so running both engages two glucose-lowering mechanisms at once — as does adding metformin or berberine on top.

Supplies

U-100 insulin syringes, 0.3 mL / 30-unit. Half-unit gradations matter at these draw volumes.
Bacteriostatic water, 10 mL bottle.
Alcohol prep pads and a sharps container.
A second 15 mg vial before Day 43 of the schedule.

Record keeping

Log the date, units drawn, and site for every injection, alongside any symptoms. This catches gradual dose drift, and if something does go wrong it identifies exactly which step it started on.